Immune Checkpoint Inhibitor-Induced Endocrinopathies: An 8-Year Experience
Author Information
Author(s): Ata Fateen, Khan Adeel Ahmad, Algorani Emad, Alsharafi Amr Faisal Musaed, Shdid Reham Abo, Nofal Mohammad, Ibrahim Ayman R., Abdullah Loai, Annan Khalil Youssef El, Al-Bkoor Tareq Emad Hawash, Rasul Kakil Ibrahim, Elhadd Tarik, Surchi Haval
Primary Institution: Hamad Medical Corporation, Doha, Qatar
Hypothesis
What is the incidence and clinical impact of immune checkpoint inhibitor-induced endocrinopathies in cancer patients?
Conclusion
The study found a higher-than-previously known incidence of immune checkpoint inhibitor-induced endocrinopathies, particularly hypothyroidism, insulin deficiency, and hyperthyroidism.
Supporting Evidence
- The incidence of immune checkpoint inhibitor-induced endocrinopathies was found to be 26.7%.
- Primary hypothyroidism was the most common endocrinopathy, occurring in 62.4% of cases.
- Pembrolizumab was the most frequently used immune checkpoint inhibitor in the cohort, accounting for 62% of cases.
- Older age and low white blood cell count were significant predictors of developing endocrinopathies.
- Mortality rates in the cohort were 43.4%, with no significant difference between those with and without endocrinopathies.
Takeaway
This study looked at cancer patients who took special medicines called immune checkpoint inhibitors and found that many of them developed hormone problems, especially with their thyroid.
Methodology
This was a retrospective observational study that included adult cancer patients who received at least one dose of immune checkpoint inhibitors between January 2015 and January 2023.
Potential Biases
Potential selection bias due to the retrospective design and the single-center nature of the study.
Limitations
The study is retrospective, which may introduce selection bias, and it was conducted at a single center, limiting generalizability.
Participant Demographics
The median age of participants was 55 years, with a male preponderance (70.7%) and a majority of Arab ethnicity (53.5%).
Statistical Information
P-Value
0.02
Confidence Interval
95% CI (1.003–1.03)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website